Overview
Acumen provides policy analysis and data management services to help policymakers improve welfare, health, education, labor, and business programs. Working with the SPHERE Institute, Acumen delivers detailed, unbiased policy context and practical information for policy debates. Its offerings include developing internal databases, self-evaluation tools, and using administrative and survey data to generate outcomes that benefit service providers and funding organizations. The company communicates research findings clearly to broad audiences and serves a range of clients including policymakers, program operators, and other stakeholders. By combining data management with rigorous policy analysis across government, public, business, and research sectors, Acumen aims to improve public policy through better information and evidence-based decision making.
Work here?Claim your company
Simplify's take
What believers are saying
- September 30, 2026 FDA contract reached $12.9 million and extends through 2029.
- Government awards totaled $83.2 million in fiscal 2025, then surged in 2026.
- November 9, 2026 SAM notice confirms a $6 million BEST bridge preserving continuity.
What critics are saying
- FDA bridge work ends September 29, 2027 unless recompeted or extended.
- Acumen depends on federal contracts; one cancellation would immediately hit revenue.
- A loss of CMS or FDA incumbency would gut most of its 2026 backlog.
What makes Acumen unique
- Acumen embeds analytics inside CMS, FDA, CDC, and HRSA programs on long awards.
- The firm runs surveillance databases and population estimates for federal health agencies.
- Its BEST and RMADA work ties research directly to reimbursement and safety decisions.
Help us improve and share your feedback! Did you find this helpful?